GLP1R and Hypoglycemia: By demonstrating the potential benefits of these therapies in reducing insulin dosage, severe hypoglycemia, cardiovascular and renal morbidity, and overall disability and mortality, this study supports the case for increasing access to these medications in LMICs, particularly GLP-1 receptor agonists, given our finding of particularly strong benefits in terms of DALYs for this medication class.